Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986619000010/alxn10k12312018.htm
July 2021
July 2021
May 2021
May 2021
April 2021
March 2021
February 2021
February 2021
January 2021
December 2020
• | 4Q18 total revenues of $1,128.8 million, a 24 percent increase over 4Q17 and a 30 percent volume increase |
• | 4Q18 GAAP diluted EPS of $(0.20); non-GAAP diluted EPS of $2.14 |
• | 2019 guidance: revenue $4,625 to $4,700 million; GAAP diluted EPS of $6.14 to $7.26; non-GAAP diluted EPS of $9.10 to $9.30 |
• | SOLIRIS® (eculizumab) for Generalized Myasthenia Gravis (gMG) best Alexion launch in first year following regulatory approval |
• | U.S. launch underway for ULTOMIRISTM (ravulizumab-cwvz) in adults with paroxysmal nocturnal hemoglobinuria (PNH); EU and Japanese applications under review |
• | Filed U.S. and EU submissions for SOLIRIS in neuromyelitis optica spectrum disorder (NMOSD) and on track to file in Japan later in 2019 |
• | Announced collaboration with Caelum Biosciences |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986619000010/alxn10k12312018.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Alexion Pharmaceuticals, Inc..
Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0000899866-19-000010
Submitted to the SEC: Wed Feb 06 2019 9:03:21 AM EST
Accepted by the SEC: Wed Feb 06 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations